Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10369757 | 0.84 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL443306 | 0.81 | CA12 (0.56) | HSD17B10SMN1; SMN2KDM4EALDH1A1CA12 | |
| SCHEMBL4811573 | 0.81 | TSHR (0.41) | HSD17B10SMN1; SMN2MAPTKDM4EALDH1A1 | |
| SCHEMBL10942193 | 0.80 | FAAH (0.33) | KDM4ECA12CA1CA2CA9 | |
| SCHEMBL6629989 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL18920642 | 0.79 | TSHR (0.45) | MAPTALDH1A1CA12CA1CA2 | |
| SCHEMBL890155 | 0.78 | — | — | |
| SCHEMBL442310 | 0.78 | TSHR (0.44) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL28791386 | 0.78 | CA12 (0.31) | CA12CA1CA2CA9 | |
| SCHEMBL9484489 | 0.78 | CA12 (0.31) | CA12CA1CA2CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556500-A1 | SIMPLE ENZYMATIC PROCESS FOR PREPARING CEFAZOLIN | Bioferma Murcia, S.A. (ES) | 2005-07-27 | — | — | EP | claimed |
| WO-2004039997-A1 | SIMPLE ENZYMATIC PROCESS FOR PREPARING CEFAZOLIN | BIOFERMA MURCIA, S.A. (ES) | 2004-05-13 | — | — | WO | claimed |
| EP-1416054-A1 | Simple enzymatic process for preparing cefazolin | Bioferma Murcia, S.A. (ES) | 2004-05-06 | — | — | EP | claimed |
| US-20250230159-A1 | FUSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAS SIGNALLING | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2025-07-17 | — | — | US | disclosed |
| CN-114269725-B | Anti-influenza virus compound, preparation method and application thereof | 西藏海思科制药有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-115397979-A | Penicillin G acylase mutants with increased cefazolin productivity and uses thereof | 艾美科健株式会社 | 2022-11-25 | — | — | CN | disclosed |
| CN-109971743-B | Penicillin G acylase mutant derived from achromobacter CCM4824 and application thereof | 艾美科健株式会社 | 2022-09-06 | — | — | CN | disclosed |
| CN-114269725-A | Anti-influenza virus compound and preparation method and application thereof | 四川海思科制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114085193-A | Method for preparing 1H-tetrazoleacetic acid and derivatives thereof by aqueous phase method | 九江中星医药化工有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-114085193-A | Method for preparing 1H-tetrazoleacetic acid and derivatives thereof by aqueous phase method | 九江中星医药化工有限公司 | 2022-02-25 | — | — | CN | disclosed |
| WO-2021096298-A1 | PENICILLIN G ACYLASE MUTANT HAVING INCREASED CEFAZOLINE PRODUCTIVITY AND USE THEREOF | 아미코젠주식회사 | 2021-05-20 | — | — | WO | disclosed |
| WO-2004039997-A1 | SIMPLE ENZYMATIC PROCESS FOR PREPARING CEFAZOLIN | BIOFERMA MURCIA, S.A. (ES) | 2004-05-13 | — | — | WO | disclosed |
| EP-1416054-A1 | Simple enzymatic process for preparing cefazolin | Bioferma Murcia, S.A. (ES) | 2004-05-06 | — | — | EP | disclosed |
| US-4616024-A | Dihydropyridine anti-ischaemic and antihypertensive agents | PFIZER INC. (US) | 1986-10-07 | — | — | US | disclosed |
| EP-0100189-B1 | DIHYDROPYRIDINE ANTI-ISCHAEMIC AND ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1986-05-28 | — | — | EP | disclosed |
| US-4515799-A | Dihydropyridine anti-ischaemic and antihypertensive agents | PFIZER INC. (US) | 1985-05-07 | — | — | US | disclosed |
| EP-0100189-A2 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1984-02-08 | — | — | EP | disclosed |
| US-4314059-A | Process for preparing cephalosporin compounds | SHIBUYA CHISEI | 1982-02-02 | — | — | US | disclosed |
| US-4258195-A | Novel thiol esters and process for preparing cephalosporin compounds using same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1981-03-24 | — | — | US | disclosed |
| EP-0004570-A1 | Thiol esters, process for their preparation, pharmaceutical compositions containing them and a process for preparing cephalosporin compounds using the same | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230159-A1 | FUSED HETEROCYCLIC COMPOUNDS AS MODULATORS OF RAS SIGNALLING | KRAS, HRAS, NRAS | HSD17B10 3593/4885SMN1; SMN2 2749/4885MAPT 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.